MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Viridian Therapeutics ROCE Ratio 2011-2026 | VRDN
Annual ROCE Ratio Viridian Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -50.32 | -44.52 | -57.57 | -34.0 | -42.47 | -33.6 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -33.6 | -57.57 | -43.75 |
Quarterly ROCE Ratio Viridian Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -56.01 | -59.85 | -52.76 | -35.03 | -53.1 | -59.36 | -64.49 | -57.5 | -64.79 | -54.01 | -56.07 | -43.65 | -50.56 | -50.19 | -47.55 | -42.57 | -47.08 | -44.68 | -31.79 | -16.48 | -87.76 | -154.54 | -205.99 | -202.54 | -220.36 | -166.9 | -127.4 | -44.08 | -59.37 | -56.84 | -58.67 | -52.4 | -45.8 | -23.92 | 0.74 | 17.88 | -12.17 | -48.81 | -78.3 | -79.06 | -106.32 | -103.53 | -126.53 | -76.97 | -76.97 | -49.46 | -2.28 | 0.51 | 0.25 | 0.25 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17.88 | -220.36 | -64.7 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Amgen
AMGN
|
104.87 | $ 340.0 | -0.75 % | $ 183 B | USA |
 |
Amneal Pharmaceuticals
AMRX
|
14.49 | $ 12.32 | -0.24 % | $ 3.86 B | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
394.73 | - | - | $ 8.42 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 23.27 | -1.63 % | $ 2.96 B | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
Autolus Therapeutics plc
AUTL
|
-151.88 | $ 1.36 | -2.16 % | $ 362 M |  Britain |
 |
AVROBIO
AVRO
|
10.76 | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
11.12 | - | - | $ 96.9 B | Britain |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.76 | 4.35 % | $ 9.05 B |  Australia |
 |
CymaBay Therapeutics
CBAY
|
-34.79 | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
-12.81 | $ 2.57 | -3.38 % | $ 16.1 M | USA |
 |
Avid Bioservices
CDMO
|
-30.68 | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
-107.83 | - | - | $ 1.41 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Checkpoint Therapeutics
CKPT
|
444.94 | - | - | $ 169 M | USA |
 |
Cellectar Biosciences
CLRB
|
-269.17 | $ 2.75 | 1.48 % | $ 7.17 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.5 | - | - | $ 231 M | USA |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
-69.06 | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
453.99 | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-123.17 | - | -4.36 % | $ 27 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
-40.99 | $ 3.48 | -16.14 % | $ 8.76 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-60.12 | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-0.69 | - | - | $ 2.02 B | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Dyadic International
DYAI
|
-583.64 | $ 0.88 | 1.66 % | $ 31.8 M | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 89.62 | -1.82 % | $ 27.2 B | Germany |
 |
Coherus BioSciences
CHRS
|
-296.87 | $ 1.67 | - | $ 196 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-60.98 | $ 3.8 | 7.34 % | $ 256 B | Britain |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |